Abstract: Objective Evaluate the value of the combination of Carolizumab and Stereotactic Body Radiotherapy (SBRT) on survival and treatment safety in the non-surgical treatment of advanced lung cancer. Methods Retrospective analysis was conducted on 300 patients with advanced non-surgical treatment of lung cancer admitted to the Radiotherapy Department of Chifeng City Hospital from April 2020 to October 2022. According to different clinical treatment methods, they were divided into a study group (150 cases, treated with SBRT) and a control group (150 cases, treated with intravenous injection of Carolizumab every three weeks, a total of four times). Both groups were treated for 3 courses (21 days per course). Collect two sets of clinical information to compare treatment efficacy, changes in inflammatory factors (IL-6, IL-10), tumor necrosis factor (TNF-a), vascular endothelial factors (bFGF, Ang-2, VEGF, MMP-9) before and after treatment, immune status (CD4⁺, CD8⁺, NK), and adverse reactions during treatment. Results The treatment effectiveness rate of the research group was higher than that of the control group, with lower levels of IL-6 and IL-10, and higher levels of TNF-a than the control group (P<0.05); The levels of bFGF, Ang-2, VEGF, and MMP-9 in the study group were lower than those in the control group (P<0.05); After intervention, the immune T cell subpopulations CD4⁺, CD8⁺, and NK in the study group were higher than those in the control group (P<0.05); There was no statistically significant difference in adverse reactions between the two groups (P>0.05). Conclusion Karelizumab combined with SBRT in the treatment of advanced non-surgical lung cancer can improve clinical treatment efficacy, improve immune status, suppress tumor related inflammatory reactions, and reduce the incidence of adverse reactions during treatment. It has high clinical application value.

Key words: karelizumab, stereotactic body radiotherapy, middle to late stage, non surgical treatment, lung cancer